Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms- |
Target |
Action inhibitors |
Mechanism MAP3K11 inhibitors(Mitogen-activated protein kinase kinase kinase 11 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Triple Negative Breast Cancer | Preclinical | Poland | 30 Apr 2025 | |
Neoplasms | Preclinical | United States | 17 Oct 2024 | |
Neoplasms | Preclinical | United States | 17 Oct 2024 | |
Neoplasms | Preclinical | Poland | 17 Oct 2024 | |
Neoplasms | Preclinical | Poland | 17 Oct 2024 |